Ranirestat

CAS : 147254-64-6

Ref. 3D-FR103275

Informations sur le produit

• Nom: Ranirestat
• Synonymes: (3R)-2'-(4-bromo-2-fluorobenzyl)-1'H,2H,5H-spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'H)-tetrone, (3R)-2′-(4-Bromo-2-fluorobenzyl)-1′,2′,3′,4′-tetrahydrospiro[pyrrolidine-3,4′-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5-tetraone, (3R)-2′-(4-Bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4′-1′H-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetraone, (3R)-2′-[(4-Bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone, As-3201, SX-3030(racemate), SX-3202((+)-(S)-isomer), Spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone, 2′-[(4-bromo-2-fluorophenyl)methyl]-, (-)-, Spiro[pyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine]-1′,2,3′,5(2′H)-tetrone, 2′-[(4-bromo-2-fluorophenyl)methyl]-, (3R)-, Sx-3201

Description

Ranirestat is a fatty acid that is used as a pharmaceutical agent. It is known to be biocompatible and has been shown to have hepatic impairment properties. Ranirestat inhibits DPP-IV, which is an enzyme that degrades the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). It has been shown to be effective in treating diabetic patients who are not on any other medications or treatments. Ranirestat has also been shown to prevent or reduce the severity of diabetic neuropathy in animal models. This drug may provide an alternative treatment for diabetes mellitus type 2 by promoting the release of GLP-1 and GIP from intestinal cells, thereby reducing hyperglycemia and improving insulin sensitivity.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 420.19 g/mol
• Formule: C₁₇H₁₁BrFN₃O₄
• Degré de pureté: Min. 95%
• InChI: InChI=1S/C17H11BrFN3O4/c18-10-4-3-9(11(19)6-10)8-21-14(24)12-2-1-5-22(12)17(16(21)26)7-13(23)20-15(17)25/h1-6H,7-8H2,(H,20,23,25)/t17-/m1/s1
• Code InChI: InChIKey=QCVNMNYRNIMDKV-QGZVFWFLSA-N
• SMILES: O=C1C[C@@]2(C(=O)N1)C(=O)N(Cc1ccc(Br)cc1F)C(=O)c1cccn12